Glucocorticoids and rheumatoid arthritis: Back to the future?

Arthritis and Rheumatism

Volumn 46, Issue 10, 2002, Pages 2553-2563

  Moreland, Larry W ^a   O'Dell, James R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; VITAMIN D;

ACNE; ADRENAL SUPPRESSION; APPETITE DISORDER; BONE NECROSIS; BRAIN PSEUDOTUMOR; CALCIUM HOMEOSTASIS; CATARACT; CELL TYPE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDEMA; EDITORIAL; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; FATTY LIVER; FETUS MALFORMATION; FLUID RETENTION; HIRSUTISM; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INSOMNIA; INTESTINE PERFORATION; INTRAUTERINE GROWTH RETARDATION; LIPODYSTROPHY; LONG TERM CARE; MENTAL INSTABILITY; METABOLIC ALKALOSIS; MOON FACE; NONHUMAN; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; PSYCHOSIS; PURPURA; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SKIN ATROPHY; STOMACH ULCER; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS;

EID: 0036822540     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10567     Document Type: Editorial

References (151)

1. Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2):CD001158.
2. Kirwan JR. Systemic low-dose glucocorticoid treatment in rheu-matoid arthritis. Rheum Dis Clin North Am 2001;27:389-403.
3. Adcock IM, Brown CR, Gelder CM, Shirasaki H, Peters MJ, Barnes PJ. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 1995;268:C331-8.
4. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996;60:563-72.
5. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6; mediation by decreased mRNA stability. Mol Pharmacol 1993;43:176-82.
6. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of 1κBα synthesis. Science 1995;270:286-90.
7. Boss B, Neeck G, Engelhardt B, Riedel W. Influence of corticosteroids on neutrophils, lymphocytes, their subsets, and T-cell activity markers in patients with active rheumatoid arthritis, compared to healthy controls. Ann N Y Acad Sci 1999;876:198-200.
8. Cheng S, Lai C, Fausto A, Chellaiah M, Feng X, McHugh KP, et al. Regulation of αVβ3 and αVβ5 integrins by dexamethasone in normal human osteoblastic cells. J Cell Biochem 2000;77:265-76.
9. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissman G. A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992;89:9991-5.
10. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974;53:240-6.
11. Fries LF, Brickman CM, Frank MM. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune haemolytic anaemia and other haemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983;131:1240-5.
12. Goulding NJ, Euzger HS, Butt SK, Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res 1998;47:S158-65.
13. Goulding NJ, Godolphin JL, Sharland PR, Peers SH, Sampson M, Maddison PJ, et al. Anti-inflammatory lipocortin 1 is produced by peripheral blood leucocytes in response to intravenous hydrocortisone. Lancet 1990;335:1416-9.
14. Goulding NJ, Jefferiss CM, Pan L, Rigby WFC, Guyre PM. Specific binding of lipocortin-1 (annexin I) to monocytes and neutrophils is decreased in rheumatoid arthritis. Arthritis Rheum 1992;35:1395-7.
15. Guyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem 1988;30:89-93.
16. Kern JA, Laumb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of interleukin-1β production by human monocytes: post-transcriptional mechanisms. J Clin Invest 1998;81:237-44.
17. Paliogianni F, Ahuja SS, Balow JP, Balow JE, Boumpas DT. Novel mechanism for inhibition of human T-cells by glucocorticoids: glucocorticoids inhibit signal transduction through interleukin-2 receptor. J Immunol 1993;151:4081-9.
18. Rinehart JJ, Sagone AL, Balcerzak SP. Effects of corticosteroid therapy in human monocyte function. N Engl J Med 1975;292:236-41.
19. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcription activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
20. Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther 1989;250:598-605.
21. Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998;41:1203-9.
22. Smith MD, Bertouch JV, Smith AM, Weatherall M, Ahern MJ, Brooks PM, et al. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects. J Rheumatol 1988;15:229-32.
23. Youssef PP, Cormack J, Evill CA, Peter DT, Roberts-Thomson PJ, Ahern MJ, et al. Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Arthritis Rheum 1996;39:216-25.
24. Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis: reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996;39:1970-9.
25. Flower RJ, Blackwell GU. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979;278:456-9.
26. Blackwell GJ, Carnuccio R, DiRosa M, et al. Macrocortin: a polypeptide causing anti-phospholipase effect of glucocorticoids. Nature 1980;287:147-9.
27. Bloemena E, Weinreich S, Schellenkens PTA. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol 1990;80:460-6.
28. Ramdas J, Harmon JM. Glucocorticoid-induced apoptosis and regulation of NF-kappa B activity in human leukemic T-cells. Endocrinology 1998;139:3813-21.
29. Gillis S, Crabtree GR, Smith KA. Glucocorticosteroid-inducted inhibition of T-cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979;123:1624-31.
30. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-208.
31. Emkey RD, Lindsay R, Lyssy J, Weisberg JS, Dempster DW, Shen V. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:277-82.
32. Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vitro hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin Exp Immunol 1967;24:54-62.
33. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-51.
34. Ray A, LaForge KS, Sehgal PB. On the mechanism of efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990;10:5736-46.
35. Werb Z. Biochemical actions of glucocorticoids on macrophages in culture: Specific inhibition of elastase, collagenase and plasminogen activator secretion and effects on other metabolic functions. J Exp Med 1978;147:1695-712.
36. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997;40:1400-8.
37. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976;271:202-10.
38. Gottlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 1998;76:480-9.
39. Zhang G, Zhang L, Duff GW. A negative regulatory region containing a glucocorticoid response element (nGRE) in the human interleukin-1 beta gene. DNA Cell Biol 1997;16:145-52.
40. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
41. Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-21.
42. Vishwanath BS, Frey FJ, Bradbury M, Dallman M, Frey BM. Adrenalectomy decreases lipocortin-I messenger ribonucleic acid and tissue protein content in rats. Endocrinology 1992;130:858-91.
43. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone in rheumatoid arthritis: a preliminary report. Mayo Clin Proc 1949;24:181-97.
44. Bernstein CA, Freyberg FH. Rheumatoid patients after five or more years of corticosteroid treatment: a comparative analysis of 183 cases. Ann Intern Med 1961;54:938-53.
45. Empire Rheumatism Council Sub-Committee. Multi-center controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis 1955;14:353-63.
46. Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone A, and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of cortisone and aspirin in the early cases of rheumatoid arthritis. BMJ 1954;1:1223-7.
47. Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone A, and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959;18:173-87.
48. Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH, and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960;19:331-7.
49. Gotzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998;316:811-8.
50. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996;39:1818-25.
51. Harris ED Jr, Emkey RD, Nichols JE, Newberg A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983;10:713-21.
52. Messina OD, Barreira JC, Zanchetta JR, Maldonado-Cocco JA, Bogado CE, Sebastian ON, et al. Effect of low doses of deflazacort vs. prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992;19:1520-6.
53. Million R, Poole P, Kellgren JH, Jayson MI. Long-term study management of rheumatoid arthritis. Lancet 1984;1:812-6.
54. Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharmacol Res 1992;XII;11-8.
55. Van Gestel AM, Laan RFJM, Haagsma CJ, van de Putte LBA, van Riel PLCM. Low-dose oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold: a randomized double-blind placebo-controlled trial. Br J Rheumatol 1995;34:347-51.
56. Van Schaardenburg D, Valkema R, Dijkmans BAC, Papapoulos S, Zwinderman AH, Han KH, et al. Prednisone treatment of elderly-onset rheumatoid arthritis: disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum 1995;38:334-42.
57. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJTO, van't Hof MA, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;119:963-8.
58. Schoger GA. Zur beurteilung der wirkung einer kombination von salicylaten und prednisolon bei rheumatischen erkrankungen. Arzneimittelforschung 1968;18:758-60.
59. Lee P, Anderson JA, Miller J, Webb J, Buchanan WW. Evaluation of analgesic action and efficacy of antirheumatic drugs. J Rheumatol 1976;3:283-94.
60. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
61. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
62. Lipsky PE, van der Heijde D, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
63. Kirwan JR, the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
64. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481-91.
65. Hickling P, Jacoby RK, Kirwan JR, the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930-6.
66. Wilske K, Healey L. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
67. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
68. Landewé RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MAFJ, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
69. Van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma WJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
70. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999;58:713-8.
71. Paulus HE, di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT, et al, the Long-Term Etodolac Study Investigators. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 2000;27:1632-7.
72. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994;21:1207-13.
73. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
74. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
75. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
76. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
77. Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978;64:729-31.
78. Alavi IA, Sharma BK, Pillay VKG. Steroid-induced diabetic ketoacidosis. Am J Med Sci 1971;262:15-23.
79. Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O. Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967;26:18-24.
80. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993;95:258-64.
81. Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 1979;66:910-4.
82. Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med 1980;68:224-30.
83. Reinisch JM, Simon N, Karow W, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-8.
84. Smith KD, Steingerger E, Rodriquez L. Prednisone therapy and birth weight. Science 1979;296:96-7.
85. Rayburn WF. Glucocorticoid therapy for rheumatic diseases: maternal, fetal and breast-feeding considerations. Am J Reprod Immunol 1992;28:138-40.
86. Bollet AJ, Black R, Bunim JJ. Major undesirable side-effects resulting from prednisolone and prednisone. JAMA 1955;158:459-63.
87. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of noncorticosteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
88. Messer J, Reitman B, Sacks HS, Smith Hi, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-4.
89. Nelp WB. Acute pancreatitis associated with steroid therapy. Arch Intern Med 1961;108:702-10.
90. Sterioff S, Orringer M, Cameron J. Colon perforations associated with steroid therapy. Surgery 1974;75:56-8.
91. Canter JW, Shorb PE Jr. Acute perforation of colonic diverticula associated with prolonged adrenocorticosteroid therapy. Am J Surg 1971;121:46-51.
92. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;115:787-96.
93. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396-402.
94. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989;30:135-9.
95. Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980;98:1773-7.
96. Berkowitz JS, David DS, Sakai S, Shoji H, Cheigh JS, Riggio RR, et al. Ocular complications in renal transplant recipients. Am J Med 1973;55:492-5.
97. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-50.
98. Garbe E, LeLorier J, Boivin J-F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.
99. Furst C, Smiley WK, Ansell BM. Steroid cataract. Ann Rheum Dis 1996;25:364-7.
100. Giles CL, Mason GL, Duff IF, McLean JA. The association of cataract formation and systemic corticosteroid therapy. JAMA 1962;182:719-22.
101. David DS, Berkowitz JS. Ocular effects of topical and systemic corticosteroids. Lancet 1969;2:149-51.
102. Jackson SHD, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981;61:381s-383s.
103. Kalbak K. Incidence of arteriosclerosis in patients with rheumatoid arthritis receiving long-term corticosteroid therapy. Ann Rheum Dis 1972;31:196-200.
104. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972;49:329-36.
105. Moreland LW, Bridges SL Jr. Early rheumatoid arthritis: a medical emergency? Am J Med 2001;111:498-500.
106. Raynauld J-P. Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids? J Rheumatol 1997;24:415-6.
107. Jacobsson LTH, Turesson C, Hanson RL, Pillemer S, Sievers ML, Pettitt DJ, et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001;44:1170-6.
108. Wallberg-Jonsson S, Johansson H, Ohman M, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999;26:256-7.
109. Hall GM, Spector TD, Griffin AJ, Jawad ASM, Hall ML, Doyle DV. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993;36:1510-6.
110. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43:522-30.
111. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
112. Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular bone mass in post menopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol 1997;36:43-9.
113. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
114. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
115. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986;45:950-3.
116. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Tartarotti D, Galvanini G, et al. Bone loss after glucocorticoid therapy. Bone Miner 1984;8:39-51.
117. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
118. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
119. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-8.
120. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997;24:1495-503.
121. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989;48:535-8.
122. Gough KS, Lilley J, Eyre S, Holder RL, Emery P. Generalized bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
123. Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC. Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 1995;10:257-63.
124. Towheed TE, Bronillard D, Yendt E, Anastassiades T. Osteoporosis in rheumatoid arthritis: findings in the metacarpal, spine, and hip and a study of the determinants of both localized and generalized osteopenia. J Rheumatol 1995;22:440-3.
125. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in Women with rheumatoid arthritis [letter]. BMJ 1993;306:558.
126. Cooper C, Coupland C, Mitchell NI. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
127. Michel BA, Bloch DA, Fries JF, Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
128. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
129. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy: a comparison with daily therapy. Arthritis Rheum 1981;24:892-8.
130. Baltzan MA, Suissa S, Bauer DC, Cummings SR. Hip fractures attributable to corticosteroid use [letter]. Lancet 1999;353:1327.
131. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990;150:2545-8.
132. Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995;85:1693-5.
133. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991;338:60-1.
134. Kroger H, Honaken R, Saarikoski S, Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis - a population based study. Ann Rheum Dis 1994;53:18-23.
135. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999;42:1246-54.
136. Guyatt GH, Webber CE, Mewa AA, Sackett DL. Determining causation - a case study: adrenocorticosteroids and osteoporosis. J Chronic Dis 1984;37:343-52.
137. Wasnick RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
138. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998;25:1282-9.
139. Peel NFA, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
140. Olgaard K, Storm T, Wowern NV, Daugaard H, Edfjord M, Lewis E, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992;50:490-7.
141. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503.
142. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
143. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
144. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
145. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
146. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
147. Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 2001;161:1522-5.
148. Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 2001;28:1298-305.
149. Orisi M, Saag MG, Ford AM, Moreland LW. Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clin Rheumatol 2000;6:117-22.
150. Afifi AK, Bergman A, Harvey JC. Steroid myopathy. Johns Hopkins Med J 1968;123:158-74.
151. Askari A, Vignos PJ, Moskowitz R. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-91.